Tag: LateBreaking
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at…...
XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in...
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST…...
– Post-hoc analysis results with VOWST highlight the importance of gut microbiome diversity as a critical component of a treatment regimen to reduce...
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomeni… –...
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) –– 33% (2/6) of patients with...
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant … –...
Extensive updates from broad and innovative portfolio also to be presented
The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the...
Late-Breaking Data from Landmark COAPT Trial Show Long-Term Benefits of Abbott’…...
New five-year data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine reinforce...
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2...
CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. EVLO, a clinical stage biotechnology company developing SINTAX™ medicines as...
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent®...
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularisDupixent significantly reduced itch at 12...
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in...
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect...
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586...
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activityRobust in vivo tumor regression observed with once daily oral dosingPharmacodynamic biomarkers of...
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session...
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated ...